Mode
Text Size
Log in / Sign up
Phase 3 N=6 Randomized Treatment

Effects of Electrical Stimulation and Vitamin D Supplementation on Bone Health Following Spinal Cord Injury.

Spinal Cord Injury

Enrolled (actual)
6
Serious AEs
0.0%
Results posted
Jan 2026
Primary outcome: Primary: Change in Trabecular Plate Width (Tb.PW) for Femur and Tibia at 4.5 Months — 1785.42; 1819.41; 1805.52; 1834.67 μm

Study Design & Population

Study type
Interventional
Phase
Phase 3
Interventions
NMES (Device); Vitamin D (Drug); Passive movement (Behavioral)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
VA Office of Research and Development
Primary completion
Jun 2024

Outcome Measures

OutcomeResultp-value
PRIMARY
Change in Trabecular Plate Width (Tb.PW) for Femur and Tibia at 4.5 Months
1785.42; 1819.41; 1805.52; 1834.67
PRIMARY
Change in Trabecular Plate Width (Tb.PW) for Femur and Tibia at 9 Months
1767.38; 1750.77; 1786.44; 1734.01
PRIMARY
Change in Trabecular Spacing (Tb.Sp) for Femur and Tibia at 4.5 Months
550.41; 463.22; 556.84; 440.57
PRIMARY
Change in Trabecular Spacing (Tb.Sp) for Femur and Tibia at 9 Months
494.33; 526.39; 484.05; 565.33
PRIMARY
Change in Trabecular Network Area Density (Tb.NA) Measured in mm^2/mm^3) at 4.5 Months
0.48; 0.59; 0.45; 0.46
PRIMARY
Change in Trabecular Network Area Density (Tb.NA) as Measured by MRI at 9 Months
0.52; 0.48; 0.54; 0.44
SECONDARY
Change in Bone Mineral Density in Distal Femur as Measured by Dual Energy X-ray Absorptiometry (DXA) Scan
0.94; 1.17; 0.90; 1.21
SECONDARY
Change in Distal Femur Bone Mineral Density
0.84; 1.07; 0.84; 1.02
SECONDARY
Change in Proximal Tibia Bone Mineral Density (BMD) as Measured by Dual-energy X-ray Absorptiometry (DXA) Scan
0.97; 1.47; 1.09; 1.42
SECONDARY
Change in Proximal Tibia Bone Mineral Density as Measured by a Dual-energy X-ray Absorptiometry (DXA) Scan
1.02; 1.3; 1.09; 1.24
SECONDARY
Change in Bone Formation Marker - Procollagen Type 1 N-terminal Propeptide (P1NP) in mcg/L
38; 53
SECONDARY
Change in Bone Formation Marker - Procollagen Type 1 Intact N-Propeptide (P1NP) Measured in mcg/L
35; 34
SECONDARY
Change in Bone Resorption Marker-C-telopeptide of Type I Collagen (CTX)
333; 306
SECONDARY
Change in Bone Resorption Marker-C-telopeptide of Type I Collagen (CTX)
333; 306
SECONDARY
Change in Serum 25-hydroxyvitamin D [25(OD)D] Level
32.1; 37.15
SECONDARY
Change in Serum 25-hydroxyvitamin D Level
49.4; 50.7
SECONDARY
Change in Quality-of-life Measure: Physical Health (Scored on 1-5 Likert Scale)
75; 69
SECONDARY
Change in Quality-of-life Measure- Psychological Health
81; 81
SECONDARY
Change in Quality-of-life Measure- Social Relationships Domain
69; 75
SECONDARY
Change in Quality-of-life Measure-environmental Engagement Domain
75; 75

Summary

Neurogenic osteoporosis is a common complication of spinal cord injury (SCI) that is associated with low impact bone fractures. It is concerning that more than 46,000 Veterans affected with SCI and are at risk of osteoporosis and possible low impact fractures. About fifty percent of all individuals with SCI will develop low impact fracture in their life time. The management of osteoporosis-related fractures can impose substantial economic burden on the health care system, the individual and the families. Previous studies did not succeed in reversing the process of bone loss after SCI. In the present pilot study, we will evaluate the effect of Neuromuscular Electrical Stimulation Resistance Training in combination with oral Vitamin D supplementation, on bone quality in Veterans with chronic SCI, using a randomized experimental design.

Eligibility Criteria

Inclusion Criteria

To be included, participants will have to:

  • Be 18-65 years of age
  • Have history of traumatic SCI ( 1-year) with NLI of C8-T10 and AIS A or B (confirmed by AIS examination performed by PI or a qualified Provider
  • Have a caregiver who is available and willing to be trained to apply intervention protocol in the home (placing weights and positioning the Veteran) throughout study duration
  • Be a wheelchair user for primary mode of mobility
  • Have Knee extensors that must respond to standard surface electrical stimulation procedures (stimulation frequency procedures, 30 Hz; pulse duration:1 ms and amplitude of the current of less than200 mA)
  • Be able to receive written clearance from their medical Providers to ensure safety of participants
  • Be a Veteran (male or female), however, the Department of Veteran Affairs has limited number of female Veterans, especially those with motor complete injury at level C8-T10 (currently, there are only 3 female Veterans with the target NLI in our SCI registry). Hence, inclusion of women Veterans may be challenging due to this disparity in the SCI population. If we fail to recruit 20 Veterans, we may seek an IRB approval to recruit non-Veterans to meet our target sample size
  • Have normal ECG
  • Commit to undergo 9 months of trial; 4.5 months of open-kinematic chain resistance training followed by 4.5 months of closed-kinematic chain using simple rowing approach + Vit. D supplementation (Experimental group) or 9 months of passive movement +Vit D supplementation (control group)

Exclusion Criteria

Potential participants will be excluded if they exhibit any of the following:

  • Neurological injury other than SCI
  • Older than 65 years of age as they may likely have considerable amount of bone loss at that age
  • Have severe osteoporosis because loading porous/fragile bone by electrical stimulation may result in bone fracture
  • Those classified as AIS C & D, as they may already be engaging in weight bearing activities that may confound the results of this trial
  • Unhealed or unstable fractures in either lower or upper extremities
  • Severe scoliosis, deformities in the hip, knee, or ankles OR impaired range-of-motion, as these could be a barrier to safe positioning on the rowing machine, and on MRI or DXA tables
  • No caregiver or family member/significant other, willing to help with placing weights and positioning participants' lower extremities on the rowing machine
  • Untreated or uncontrolled hypertension (systolic blood pressure (BP) > 140 mmHg; diastolic BP > 90 mmHg), and/or sudden hypotension upon transferring from bed to wheelchair, characterized by a drop in BP by 20 mmHg (especially in persons with tetraplegia) or heart rate > 100 beats per minute
  • Anti-coagulation or anti-platelet therapy (including aspirin)
  • Implanted pacemakers, implanted defibrillator devices or any metallic implants including knee or hip implants
  • Presence of bullets in vertebral column or shrapnel anywhere in the body that may interfere with MRI procedure
  • Other medical conditions including cardiovascular disease, uncontrolled type II DM, active deep vein thrombosis (DVT), uncontrolled autonomic dysreflexia, use of insulin for DM management, pressures injuries of stage 3 or higher, or active urinary tract infection
  • Severe hypercalcemia (serum calcium > 16mg/dl), stage III-V kidney disease, post-menopausal or estrogen dependent female, and men undergoing anti-androgen therapy or are post orchiectomy
  • DXA total body T-score less than -2.5. Total hip BMD T-scores < -3.5 and knee BMD scores of less than 0.6 g/cm2
  • Untreatable severe spasticity bearing on potential participants' activities of daily living, such as transfers from bed to wheelchair or maintaining position in wheelchair
  • Any psychiatric illness confounding judgment or cognitive impairment in participant or caregiver who is expected to help participant in the trial
  • Those with prosthetic lower limbs
  • Any condition that, in the
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05008484). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search